Carlsbad, CA and Cologne, Germany – October 24, 2016: How can we stay healthy through the human life cycle? What role will novel cell and gene therapies play in achieving this goal? When will new treatments be available and at what price? These and many more industry-relevant questions will be addressed when the doors open at BIO-Europe® 2016, a global life science partnering event starting on November 7. The conference will once again bring leaders in the life sciences together to meet and forge partnerships that propel global drug development. High-level executives from pharma, biotech, the investment sector and patient groups are already confirmed to attend, and will lead program panels and discussions relevant to the industry.
Featured speakers
? Kim Andersen – Senior VP and Head of Research, H. Lundbeck A/S
? Julia Berretta – VP, Business Development, Cellectis
? Kate Bingham – Managing Partner and EU Deal Team, SV Life Sciences Advisers
? Paul Biondi – Senior VP, Head of Business Development, BMS
? Sylvie Bove – CEO, EIT Health
? Jeanette Evans – Executive Director, Business Development and Licensing, MSD
? Jonathan Garen – Chief Business Officer, UniQure
? Debra Miller – President and CEO, CureDuchenne/CureDuchenne Ventures
? Jörg Möller – VP, Head Global Business Development, Bayer
? Nerida Scott – Senior Director, Transactions, Johnson & Johnson Innovation
? Rehan Verjee – Chief Marketing and Strategy Officer, Merck KGaA
? Juergen Windeler – Director, Institute for Quality and Efficiency in Health Care, IQWiG
Hot topics
? Value and the pricing of innovation
? Your microbiome and lifelong health
? Navigating the post-deal landscape
? An autobahn for rare drug development
? Immunotherapies: Partnership models driving cures
Program Highlights
Spotlight Track: The human healthcycle
Beginning with an insightful discussion about the lifelong health impact of our individual microbiomes, this year’s spotlight track will shine a light on the diseases, and the biotech breakthroughs to treat them, that are prevalent at each stage of the human healthcycle. From factors that affect infant immune development to the lifestyle diseases that emerge at middle age, from childhood allergies and vaccinations to the neurological diseases associated with ever longer lifespans, this track will address the treatments, technologies and systems developed and adopted by healthcare systems to manage the intricacies of the human healthcycle.
Partnerships in Cell and Gene Therapies
Cell and gene therapies continue to attract the interest of the entire healthcare spectrum from investors to biotechs, pharmas to patient groups. The Cell and Gene Therapies track at BIO-Europe will zero in on those areas in which innovation is a driving force of change and development. A dedicated panel on cancer therapies will begin the track, followed by a second deep-dive into immunotherapies. The possibilities for this sector resulting from new efforts of patient engagement will then be examined, followed by an in-depth discussion about the unique commercialization challenges for cell and gene therapy products.
Registration and event information is available online.
Watch video coverage from previous events, interviews with executives and thought leaders in the life science industry and premier content related to the biopharma industry on EBD Group’s Insight.
